申请人:Dae Woong Pharmaceutical Co., Ltd.
公开号:US05336673A1
公开(公告)日:1994-08-09
The present invention relates to novel cephalosporins of the formula (I); ##STR1## wherein, R.sub.1 represents a C.sub.1 .about.C.sub.4 alkyl group or ##STR2## wherein, R.sub.2 and R.sub.3, independently, represent hydrogen or a C.sub.1 .about.C.sub.3 alkyl group and R.sub.4 represents hydrogen or a C.sub.1 .about.C.sub.4 alkyl group; R.sub.1a represents hydrogen or an amino-protecting group; Q represents CH or N; and the formula ##STR3## represents a saturated or unsaturated heterocyclic group which contains 1 to 4 nitrogen atoms of which one is substituted with an amino group to form quaternary ammonium, and oxygen or sulfur, or a fused heterocyclic group thereof formed together with a substituted or unsubstituted benzene or an optional heterocyclic group, or a pharmaceutically acceptable salt thereof, to processes for preparing the same and to a pharmaceutical composition containing the same as an active ingredient. The compounds(1) according to the invention exhibit potent antibacterial activity and broad antibacterial spectrum against the Gram-positive strains including Staphylococcus as well as Gram-negative strains including Pseudomonas, and, therefore, are expected to be very useful in treatment of various diseases caused by bacterial infection in human beings and animals.
本发明涉及一种新型头孢菌素,其化学式为(I);其中,R.sub.1代表一个C.sub.1到C.sub.4烷基或##STR2##其中,R.sub.2和R.sub.3独立地代表氢或一个C.sub.1到C.sub.3烷基,R.sub.4代表氢或一个C.sub.1到C.sub.4烷基;R.sub.1a代表氢或氨基保护基;Q代表CH或N;以及化学式##STR3##代表一个饱和或不饱和的杂环基,其中含有1到4个氮原子,其中一个氮原子被氨基取代形成季铵盐,还有氧或硫,或者与一个取代苯或未取代的苯或一个可选的杂环基一起形成的融合杂环基,或其药学上可接受的盐,以及制备这些化合物的方法和包含这些化合物作为活性成分的药物组合物。根据本发明的化合物(1)表现出强大的抗菌活性和广泛的抗菌谱,包括对金黄色葡萄球菌等革兰氏阳性菌株和假单胞菌等革兰氏阴性菌株,因此,预计在治疗人类和动物因细菌感染引起的各种疾病中非常有用。